Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.31
USPH's Cash to Debt is ranked higher than
72% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 0.28 vs. USPH: 0.31 )
USPH' s 10-Year Cash to Debt Range
Min: 0.25   Max: 293.61
Current: 0.31

0.25
293.61
Equity to Asset 0.57
USPH's Equity to Asset is ranked higher than
81% of the 231 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. USPH: 0.57 )
USPH' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.81
Current: 0.57

0.3
0.81
Interest Coverage 72.06
USPH's Interest Coverage is ranked higher than
88% of the 160 Companies
in the Global Medical Care industry.

( Industry Median: 6.09 vs. USPH: 72.06 )
USPH' s 10-Year Interest Coverage Range
Min: 2.29   Max: 9999.99
Current: 72.06

2.29
9999.99
F-Score: 4
Z-Score: 4.99
M-Score: -3.08
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.68
USPH's Operating margin (%) is ranked higher than
86% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 9.44 vs. USPH: 14.68 )
USPH' s 10-Year Operating margin (%) Range
Min: -10.47   Max: 20.94
Current: 14.68

-10.47
20.94
Net-margin (%) 4.82
USPH's Net-margin (%) is ranked higher than
73% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 5.38 vs. USPH: 4.82 )
USPH' s 10-Year Net-margin (%) Range
Min: -16.28   Max: 8.97
Current: 4.82

-16.28
8.97
ROE (%) 9.92
USPH's ROE (%) is ranked higher than
74% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 9.51 vs. USPH: 9.92 )
USPH' s 10-Year ROE (%) Range
Min: -63.64   Max: 39.06
Current: 9.92

-63.64
39.06
ROA (%) 5.68
USPH's ROA (%) is ranked higher than
81% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 3.98 vs. USPH: 5.68 )
USPH' s 10-Year ROA (%) Range
Min: -19.31   Max: 20.69
Current: 5.68

-19.31
20.69
ROC (Joel Greenblatt) (%) 131.98
USPH's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 17.97 vs. USPH: 131.98 )
USPH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -18.37   Max: 131.98
Current: 131.98

-18.37
131.98
Revenue Growth (%) 7.10
USPH's Revenue Growth (%) is ranked higher than
73% of the 180 Companies
in the Global Medical Care industry.

( Industry Median: 7.20 vs. USPH: 7.10 )
USPH' s 10-Year Revenue Growth (%) Range
Min: 7.1   Max: 29.5
Current: 7.1

7.1
29.5
EBITDA Growth (%) 3.40
USPH's EBITDA Growth (%) is ranked higher than
69% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 7.20 vs. USPH: 3.40 )
USPH' s 10-Year EBITDA Growth (%) Range
Min: -0.2   Max: 28
Current: 3.4

-0.2
28
EPS Growth (%) 3.20
USPH's EPS Growth (%) is ranked higher than
67% of the 144 Companies
in the Global Medical Care industry.

( Industry Median: 9.30 vs. USPH: 3.20 )
USPH' s 10-Year EPS Growth (%) Range
Min: -1.2   Max: 57.8
Current: 3.2

-1.2
57.8
» USPH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

USPH Guru Trades in Q1 2013

Jim Simons 522,700 sh (New)
Joel Greenblatt 56,057 sh (+17.21%)
Chuck Royce 1,568,494 sh (+11.9%)
John Keeley 43,030 sh (+4.37%)
» More
Q2 2013

USPH Guru Trades in Q2 2013

Chuck Royce 1,793,211 sh (+14.33%)
Jim Simons 548,400 sh (+4.92%)
John Keeley 43,170 sh (+0.33%)
Joel Greenblatt Sold Out
» More
Q3 2013

USPH Guru Trades in Q3 2013

Joel Greenblatt 36,550 sh (New)
Jim Simons 570,700 sh (+4.07%)
John Keeley 43,170 sh (unchged)
Chuck Royce 1,782,325 sh (-0.61%)
» More
Q4 2013

USPH Guru Trades in Q4 2013

Jim Simons 599,000 sh (+4.96%)
Joel Greenblatt Sold Out
Chuck Royce 1,655,407 sh (-7.12%)
John Keeley 31,420 sh (-27.22%)
» More
» Details

Insider Trades

Latest Guru Trades with USPH

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Sold Out 0.04%$29.5 - $35.35 $ 32.35-1%0
John Keeley 2013-12-31 Reduce -27.22%0.01%$29.5 - $35.35 $ 32.35-1%31420
Joel Greenblatt 2013-09-30 New Buy0.04%$27.53 - $31.24 $ 32.3510%36550
Joel Greenblatt 2013-06-30 Sold Out 0.08%$22.97 - $31.37 $ 32.3522%0
Joel Greenblatt 2012-12-31 New Buy0.08%$22.72 - $27.94 $ 32.3523%47826
John Keeley 2012-09-30 Reduce -67.61%0.05%$23.95 - $28.01 $ 32.3523%40030
Joel Greenblatt 2012-06-30 Sold Out 0.02%$22.82 - $25.33 $ 32.3535%0
Joel Greenblatt 2012-03-31 New Buy0.02%$18.88 - $23.16 $ 32.3568%10643
John Keeley 2011-12-31 Add 36.02%0.01%$17.1 - $20.91 $ 32.3569%105740
John Keeley 2011-03-31 New Buy0.02%$19 - $22.59 $ 32.3559%71900
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 30.70
USPH's P/E(ttm) is ranked higher than
53% of the 175 Companies
in the Global Medical Care industry.

( Industry Median: 21.80 vs. USPH: 30.70 )
USPH' s 10-Year P/E(ttm) Range
Min: 8.86   Max: 33.21
Current: 30.7

8.86
33.21
P/B 2.80
USPH's P/B is ranked higher than
53% of the 222 Companies
in the Global Medical Care industry.

( Industry Median: 2.29 vs. USPH: 2.80 )
USPH' s 10-Year P/B Range
Min: 1.12   Max: 4.75
Current: 2.8

1.12
4.75
P/S 1.48
USPH's P/S is ranked higher than
51% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 1.37 vs. USPH: 1.48 )
USPH' s 10-Year P/S Range
Min: 0.49   Max: 2.1
Current: 1.48

0.49
2.1
PFCF 9.80
USPH's PFCF is ranked higher than
86% of the 165 Companies
in the Global Medical Care industry.

( Industry Median: 15.52 vs. USPH: 9.80 )
USPH' s 10-Year PFCF Range
Min: 3.33   Max: 17.74
Current: 9.8

3.33
17.74
EV-to-EBIT 11.60
USPH's EV-to-EBIT is ranked higher than
83% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 17.82 vs. USPH: 11.60 )
USPH' s 10-Year EV-to-EBIT Range
Min: 3.9   Max: 12.4
Current: 11.6

3.9
12.4
PEG 3.60
USPH's PEG is ranked lower than
57% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 2.00 vs. USPH: 3.60 )
USPH' s 10-Year PEG Range
Min: 0.64   Max: 4.32
Current: 3.6

0.64
4.32
Shiller P/E 25.00
USPH's Shiller P/E is ranked higher than
63% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 24.97 vs. USPH: 25.00 )
USPH' s 10-Year Shiller P/E Range
Min: 10.64   Max: 37.28
Current: 25

10.64
37.28

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.30
USPH's Dividend Yield is ranked lower than
60% of the 139 Companies
in the Global Medical Care industry.

( Industry Median: 1.70 vs. USPH: 1.30 )
USPH' s 10-Year Dividend Yield Range
Min: 0.31   Max: 1.74
Current: 1.3

0.31
1.74
Dividend Payout 0.28
USPH's Dividend Payout is ranked higher than
73% of the 108 Companies
in the Global Medical Care industry.

( Industry Median: 0.36 vs. USPH: 0.28 )
USPH' s 10-Year Dividend Payout Range
Min: 0.18   Max: 0.38
Current: 0.28

0.18
0.38
Yield on cost (5-Year) 1.30
USPH's Yield on cost (5-Year) is ranked lower than
65% of the 144 Companies
in the Global Medical Care industry.

( Industry Median: 2.09 vs. USPH: 1.30 )
USPH' s 10-Year Yield on cost (5-Year) Range
Min: 0.31   Max: 1.74
Current: 1.3

0.31
1.74
Share Buyback Rate -0.60
USPH's Share Buyback Rate is ranked higher than
80% of the 163 Companies
in the Global Medical Care industry.

( Industry Median: -1.40 vs. USPH: -0.60 )
USPH' s 10-Year Share Buyback Rate Range
Min: 2   Max: -6.3
Current: -0.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.80
USPH's Price/DCF (Projected) is ranked higher than
84% of the 122 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. USPH: 0.80 )
USPH' s 10-Year Price/DCF (Projected) Range
Min: 0.54   Max: 2.31
Current: 0.8

0.54
2.31
Price/Median PS Value 1.20
USPH's Price/Median PS Value is ranked higher than
61% of the 206 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. USPH: 1.20 )
USPH' s 10-Year Price/Median PS Value Range
Min: 0.47   Max: 2.12
Current: 1.2

0.47
2.12
Price/Peter Lynch Fair Value 3.00
USPH's Price/Peter Lynch Fair Value is ranked lower than
64% of the 58 Companies
in the Global Medical Care industry.

( Industry Median: 1.50 vs. USPH: 3.00 )
USPH' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.47   Max: 4.08
Current: 3

0.47
4.08
Earnings Yield (Greenblatt) 8.60
USPH's Earnings Yield (Greenblatt) is ranked higher than
85% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 5.50 vs. USPH: 8.60 )
USPH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 8.1   Max: 25.6
Current: 8.6

8.1
25.6
Forward Rate of Return (Yacktman) 14.15
USPH's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 169 Companies
in the Global Medical Care industry.

( Industry Median: 11.19 vs. USPH: 14.15 )
USPH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 12.1   Max: 26.4
Current: 14.15

12.1
26.4

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Traded in other countries:UPH.Germany
U.S. Physical Therapy is incorporated in the state of Nevada. The Company together with its subsidiaries operates outpatient physical and occupational therapy clinics that provide pre- and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries. At December 31, 2012, it operated 431 clinics, inclusive of the two clinics that perform physician services, in 43 states. The average age of the 431 clinics in operation at December 31, 2012 was 8.7 years. There were 329 clinics operated under Clinic Partnerships and 102 were operated as Wholly-Owned Facilities. Its clinics are concentrated in the states including: Tennessee, Texas, Michigan, Maryland, Washington, New Jersey, Wisconsin, Georgia, Arizona, Virginia, Indiana, Florida and Maine. As on 31 December, 2012, the Company also managed 15 physical therapy practices for third parties, including physicians. It operates two clinics which specialize in the outpatient, non-surgical treatment of osteo arthritis degenerative joint disease and other musculoskeletal conditions ("Physician Services") and perform certain services on behalf of third parties that provide physical therapy services. The Company mainly operates through subsidiary clinic partnerships in which it owns a 1% general partnership interest and a 64% limited partnership interest and the managing therapist(s) of the clinics owns the remaining limited partnership interest in the majority of the clinics. Therapists at the company's clinics initially perform an evaluation of each patient, which is then followed by a treatment plan specific to the injury as prescribed by the patient's physician. The treatment plan might include a number of procedures, including therapeutic exercise, manual therapy techniques, ultrasound, electrical stimulation, hot packs, iontophoresis, education on management of daily life skills and home exercise programs. The Company focuses its marketing efforts mainly on physicians, including orthopedic surgeons, neurosurgeons, physiatrists, internal medicine physicians, podiatrists, occupational medicine physicians and general practitioners. The Company faces competition from local, regional or national entities. The Company and its clinics are subject to federal and state laws prohibiting entities and individuals from knowingly and willfully making claims to Medicare, Medicaid and other governmental programs and third party payors that contain false or fraudulent information.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide